JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kyaw, M. H.
Right arrow Articles by Campbell, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kyaw, M. H.
Right arrow Articles by Campbell, H.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2002, p. 1834-1837, Vol. 40, No. 5
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.5.1834-1837.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Invasive Meningococcal Disease in Scotland, 1994 to 1999, with Emphasis on Group B Meningococcal Disease

Moe H. Kyaw,1,2* Stuart C. Clarke,3 Peter Christie,2 Ian G. Jones,2 and Harry Campbell1

Public Health Sciences, University of Edinburgh, Edinburgh,1 Scottish Centre for Infection and Environmental Health,2 Scottish Meningococcus and Pneumococcus Reference Laboratory, Glasgow, United Kingdom3

Received 6 September 2001/ Returned for modification 9 December 2001/ Accepted 3 February 2002

A review was carried out on 774 invasive meningococcal isolates reported to the active meningococcal surveillance system in Scotland from 1994 to 1999. This showed that serogroups B (51.7%) and C (39.2%) caused the majority of disease. The six common PorB proteins (4, 1, 15, 2B, 12, and 21) and PorA proteins (serosubtypes) (P1.4, P1.15, P1.9, P1.14, P1.7, and P1.16) accounted for 50 and 51% of all group B isolates, respectively, during the study period.

* Corresponding author. Mailing address: Scottish Centre for Infection and Environmental Health, Clifton House, Clifton Place, Glasgow, G3 7LN, United Kingdom. Phone: 0141-300-1184. Fax: 0141-300-1170. E-mail: Moe.Kyaw{at}scieh.csa.scot.nhs.uk.

Journal of Clinical Microbiology, May 2002, p. 1834-1837, Vol. 40, No. 5
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.5.1834-1837.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2002 by the American Society for Microbiology. All rights reserved.